Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

The Journal of Urology

Volumn 154, Issue 6, 1995, Pages 2110-2114

  Soloway, Mark S ^a,b   Schellhammer, Paul F ^a,b   Smith, Joseph A Jr ^a,b   Chodak, Gerald W ^a,b   Vogelzang, Nicholas J ^a,b   Kennealey, Gerard T ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; BICALUTAMIDE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GYNECOMASTIA; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0028786511     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66709-0     Document Type: Article

References (24)

1. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
2. Casodex: preclinical studies
3. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing
4. A new non-steroidal anti-androgen.
5. Phase III studies to compare goserelin (ZOLADEX) with orchiectomy and with diethylstilbestrol in the treatment of prostatic carcinoma
6. Zoladex studies in prostatic and breast cancer
7. Criteria for response to treatment of metastatic prostatic cancer
8. Nonparametric confidence limits for survival probabilities and median survival time.
9. Casodex a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer
10. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
11. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.
12. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer The Zoladex study group
13. Pre-treatment testosterone levels: significance in androgen deprivation therapy.
14. Hormonal pattern in prostatic cancer: II.
15. Carcinoma of the prostate: relationship of pre-treatment hormone levels to survival.
16. Prognostic value of serum hormone concentrations in prostatic cancer.
17. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
18. Nilutamide.
19. Flutamide therapy for advanced prostatic cancer: a phase II study.
20. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
21. Flutamide as primary treatment for metastatic prostatic cancer.
22. A controlled trial of bicalutamide (Casodex) versus flutamide (Eulexin), each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer.
23. The pharmacokinetics of Casodex in laboratory animals.
24. Casodex--mechanisms of action and opportunities for usage